Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis.
Wojtkiewicz
Agnieszka
A
Wysocki
Mariusz
M
Fortuna
Jacek
J
Chrupek
Małgorzata
M
Matczuk
Maciej
M
Koltan
Andrzej
A
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab